The government of Countries Low has announced this Saturday the suspension of the vaccination campaign against the coronavirus with the drug developed by AstraZeneca, one day after doing the same for those people who are under 60 years old.
According to the information provided by the Dutch newspaper The Telegraph, the decision was taken during a meeting between the Ministry of Health and the National Institute of Public Health and the Environment (RVIM) in order to prevent doses from going bad.
The decision was due to the last five cases of effects secondary severe in women between the ages of 25 and 65, one of whom has died. It is the second time that the Dutch health authorities stop the use of this vaccine, after last month its inoculation was paralyzed for two weeks.
To date, some 400,000 vaccines have been administered AstraZeneca in Countries Low. The groups that have received the bulk of these vaccines have been people between 60 and 64 years old, health personnel, as well as those with Down syndrome or morbid obesity.
The authorities of Countries Low have confirmed for the moment more than 1.3 million accumulated cases of coronavirus, as well as 16,700 deaths, since the start of the pandemic.
The EMA: “It is effective”
There is still no clear evidence of the link between this death and the cases of thrombosis with vaccination, a connection that is being investigated, and it is expected to obtain some more clarity around next Wednesday, since the EMA safety committee (PRAC) plans to meet between April 6 and 9 to study the analysis and research carried out these weeks.
The EMA has reiterated on several occasions that the dose is “effective” and that it still does not see a direct link between the AstraZeneca vaccine and cases of thromboembolism, although it does not rule out this possibility, and still considers that the benefits it brings in its vaccination against Covid-19, a disease that carries a risk of hospitalization and death, outweigh any possible side effects.
Germany decided last Wednesday vaccinate people over 60 years of age with AstraZeneca only due to the risk that thromboembolisms are actually a side effect of vaccination in younger people, while Canada has put that limit at 55 years.